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Abstract
Toll-like receptors (TLRs) participate in the defence against bacterial infections that are common in patients with Chronic
Obstructive Pulmonary Disease (COPD). We studied all tagging SNPs in TLR2 and TLR4 and their associations with the level
and change over time of both FEV1 and sputum inflammatory cells in moderate-to-severe COPD. Nine TLR2 SNPs and 17
TLR4 SNPs were genotyped in 110 COPD patients. Associations of SNPs with lung function and inflammatory cells in induced
sputum were analyzed cross-sectionally with linear regression and longitudinally with linear mixed-effect models. Two SNPs
in TLR2 (rs1898830 and rs11938228) were associated with a lower level of FEV1 and accelerated decline of FEV1 and higher
numbers of sputum inflammatory cells. None of the TLR4 SNPs was associated with FEV1 level. Eleven out of 17 SNPs were
associated with FEV1 decline, including rs12377632 and rs10759931, which were additionally associated with higher
numbers of sputum inflammatory cells at baseline and with increase over time. This is the first longitudinal study showing
that tagging SNPs in TLR2 and TLR4 are associated with the level and decline of lung function as well as with inflammatory
cell numbers in induced sputum in COPD patients, suggesting a role in the severity and progression of COPD.
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Introduction
Chronic Obstructive Pulmonary Disease (COPD) is character-
ized by inflammation and tissue destruction which are partially
maintained by the innate immune defence system [1]. The innate
immune response in the airways involves the detection of
pathogen- or damage-associated molecular patterns by recognition
receptors such as Toll-like receptors (TLRs) on cell surfaces [2].
TLRs participate in the defence against viral and bacterial
infections, and such infections contribute to disease progression of
COPD. TLRs may thus have a role in COPD development and/
or progression.
Especially TLR2 and TLR4 have been studied among the
TLRs that recognize gram positive [3] and gram negative
bacteria. TLR2 and TLR4 are highly expressed on neutrophils
and monocytes/macrophages in COPD [4,5]. The expression of
TLR4, but not TLR2, is increased in neutrophils recovered from
bronchoalveolar lavage fluid of smokers with COPD and acute
respiratory failure [6] and from sputum of patients with stable
COPD [5].
The potential impact of functional single nucleotide polymor-
phisms (SNPs) in the TLR2 and TLR4 genes on COPD has been
previously investigated [7–10]. For instance Asp299Gly in the
TLR4 was shown to be associated with decreased lipopolysaccha-
ride (LPS) signal transduction [11]. Moreover, the prevalence of
Asp299Gly SNP (rs498670) in TLR4 appeared to be lower in
COPD patients than controls [8]. One study suggested that the
same SNP, rs498670, might not have a major impact on COPD
development, since no significant effects of this SNP on lung
function were found [9]. Another study focusing on TLR2 showed
that Arg677Trp (no rs designation available) and Arg753Gln
(rs5743708) are not associated with either the onset or the course
of COPD [7]. So far, other SNPs in TLR2 and TLR4, apart from
the most extensively studied SNPs mentioned above, have not
been studied in relation to COPD. Moreover, it is as yet unknown
whether the SNPs in TLR2 and TLR4 have any effect on lung
function decline or changes in the number of inflammatory cells
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involved in the innate immune response. Therefore, we investi-
gated the association of all tagging SNPs in TLR2 and TLR4 with
the level and decline of lung function and with the level and
changes in inflammatory cells in induced sputum over time of
subjects with established COPD (Groningen Leiden Universities




We included 114 patients with stage II-III COPD (according to
the GOLD criteria [12]) who participated in a two-center trial (the
GLUCOLD study [13]; study protocol available at www.
clinicaltrials.gov). Patient characteristics and methods have been
described in detail previously [13]. The patients had irreversible
airflow limitation and chronic respiratory symptoms [14] and had
neither used a course of oral steroids during the previous 3
months, nor maintenance treatment with inhaled or oral steroids
during the previous 6 months. They were current or ex-smokers
with a smoking history of $10 packyears, aged between 45 and 75
years without a history of asthma. The study was approved by the
medical ethics committees of the University Medical Centers of
Leiden and Groningen. All patients gave their written informed
consent.
Clinical characteristics
Lung function and reversibility to salbutamol were measured as
described previously [13]. Sputum induction and whole sample
processing were performed as described previously [13] according
to a validated technique [15] (details are presented in Materials
S1). The patients were in clinically stable condition and had no
symptoms or signs of respiratory tract infection for at least two
weeks prior to the study and before each visit [13].
Intervention and follow-up procedures
Patients with mild-moderate COPD were randomly assigned to
receive either 1) fluticasone propionate, 500 mg twice daily, for the
first 6 months followed by placebo, twice daily, for 24 months; 2)
fluticasone, 500 mg twice daily for 30 months; 3) fluticasone,
500 mg twice daily and salmeterol, 50 mg twice daily, in a single
inhaler for 30 months; 4) placebo, twice daily, for 30 months [16].
Selection of the TLR2 and TLR4 tagging SNPs and
genotyping
We selected the tagging SNPs in TLR2 and TLR4 according to
HapMap CEU genotype data (release 24) with an r2 threshold of
0.8 [17] and Minor Allele Frequency (MAF).1%, resulting in 9
and 17 tagging SNPs respectively. Genotyping was performed by
K-Bioscience (UK) using their patent-protected competitive allele
specific PCR system (KASPar). DNA was available from 110 out
of 114 COPD patients [18].
Statistics
Numbers of nonsquamous inflammatory cells in induced
sputum were log transformed to achieve normal distribution. We
used linear regression analyses to assess the associations of TLR2
and TLR4 SNPs with FEV1 level and with the number of
inflammatory cells in induced sputum at baseline. We adjusted our
analyses for age, gender, height, packyears and smoking status.
Linear mixed-effect (LME) models were used to asses associations
of the TLR2 and TLR4 SNPs with change in FEV1 and
inflammatory cells in induced sputum from baseline. Analyses
were adjusted for age, gender, height, smoking status, the
corresponding initial baseline variable (e.g. for FEV1 decline
adjusted for baseline FEV1), treatment, the period when there is a
change in treatment and its interaction with treatment and the
interaction of all variables with time. We performed LME models
with a random intercept at the subject’s level, assuming that data is
missing at random.
To assess the associations of the TLR2 and TLR4 SNPs with the
outcomes of the present study we used the general genetic model
with heterozygote and homozygote variants coded separately as
dummy variables and compared them with the homozygote wild
type.
Analyses were performed using SPSS version 18.0 for Windows
and values of p,0.05 (tested 2-sided) were considered statistically
significant.
Results
The clinical characteristics of COPD patients are presented in
Table 1 and the numbers of inflammatory cells in induced sputum
in Table 2.
All SNPs in TLR2 and TLR4 were in Hardy Weinberg
Equilibrium (p.0.05) and were not correlated with each other
(r2,0.8). The prevalence of the SNPs in TLR2 and TLR4 is
presented in Table S1 and Table S2.
1. SNPs in Toll-like receptor 2 and FEV1 level at baseline
and FEV1 decline
Individuals homozygote for rs1898830 and rs11938228 had a
significantly lower FEV1 level at baseline compared with wild-type
individuals [B (95%CI=2267 ml (2522.8–213.2) and
2240.2 ml (2450.3–30.1)] (Table 3). Individuals heterozygote
for rs7656411 and rs4696480 had a significantly higher FEV1 level
at baseline compared with wild-type individuals [185 ml (55.1–
316.2) and 170.2 ml (22.6–317.8) respectively] (Table 3).
Individuals heterozygote for rs1898830 and rs11938228 had a
significantly accelerated FEV1 decline compared with wild-type
individuals [22.4 ml/yr (24.4–20.4) and 22.2 ml/yr (24.2–
20.1) respectively]. Individuals homozygote for rs1898830,
rs3804099 and rs7656411 had significantly less FEV1 decline
compared with wild-type individuals [5.2 ml/yr (1.4–9.0), 3.1 ml/
yr (0.2–5.6) and 8.6 ml/yr (4.7–12.4) respectively] (Table 3).
Other SNPs were not significantly associated.
Table 1. Clinical characteristics of COPD patients.
COPD patients (n =114)
Males, n (%) 99 (86.8)
Age (years) 61.6 (7.7)
Height (cm) 175.5 (7.8)
Packyears* 41.8 (31.2–54.7)
Current smoker, n (%) 72 (63.2)
FEV1 % pred.** 56 (10)
FEV1 (L) 1.8 (0.4)
FEV1/IVC (%) 49.5 (8.8)
Data are presented as mean (standard deviation) or
*median (25th–75th percentile); FEV1 = Forced Expiratory Volume in one second;
FEV1/IVC = FEV1/Inspiratory Vital Capacity;
**% pred. = percentage of predicted value.
doi:10.1371/journal.pone.0043124.t001
TLR2 and TLR4 SNPs and COPD
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2. SNPs in Toll-like receptor 2 and inflammatory cells in
induced sputum: baseline level and changes from
baseline
At baseline, individuals heterozygote for rs11938228 had a
significantly higher number of sputum neutrophils, macrophages
and eosinophils compared with wild-type individuals [0.51 (0.02–
0.98), 0.48 (0.06–0.89) and 0.68 (0.03–1.33) respectively]
(Figure 1). Individuals heterozygote for the same SNP had a
significant decrease in sputum neutrophil numbers over time
compared with the wild-type individuals [20.03 (20.05–20.01)]
(Figure 1).
Individuals heterozygote for rs3804099 had a significant
decrease in neutrophil and macrophage numbers over time
compared with wild-type individuals [20.03 (20.05–20.01) and
20.04 (20.06–20.01) respectively] (Table S3 and Table S4).
The detailed results of the TLR2 SNPs and inflammatory cells in
induced sputum are presented in the data supplement (Table S3,
Table S4, Table S5 and Table S6).
3. SNPs in Toll-like receptor 4 and FEV1 level at baseline
and FEV1 decline
None of the TLR4 SNPs was significantly associated with FEV1
level at baseline.
Individuals homozygote for rs2737190, rs1927911, rs7846989,
rs7037117 and rs10983755 had a significantly accelerated FEV1
decline compared with wild-type individuals [25.0 ml/yr (28.7–
21.3), 25.4 ml/yr (29.6–21.1), 211.0 ml/yr (220.2–21.8),
29.1 ml/yr (215.1–23.2) and 210.7 ml/yr (219.9–21.5) re-
spectively] (Table 4).
Individuals heterozygote for rs12377632, rs11536869,
rs11536897, rs10759931 and rs11536878 had significantly less
FEV1 decline compared with wild-type individuals [2.4 ml/yr
(0.1–4.7), 6.4 ml/yr (1.1–11.7), 7.5 ml/yr (3.8–11.3), 2.6 ml/yr
(0.2–4.9) and 3.5 ml/yr (0.5–6.4) respectively] (Table 4).
4. SNPs in Toll-like receptor 4 and inflammatory cells in
induced sputum: baseline level and changes from
baseline
At baseline individuals heterozygote for rs12377632 had a
higher number of sputum neutrophils and eosinophils compared
with wild-type individuals [0.50 (0.01–0.99) and 1.20 (0.53–1.86)
respectively] (Figure 2). Individuals homozygote for the same SNP
(rs12377632) had a significantly higher number of sputum
neutrophils, macrophages and eosinophils at baseline compared
with wild-type individuals [1.01 (0.35–1.68), 0.85 (0.23–1.47) and
1.17 (0.27–2.07) respectively] and also a significant increase in
numbers over time [0.04 (0.01–0.07), 0.06 (0.02–0.09) and 0.07
(0.02–0.11) respectively] (Figure 2).
Table 2. The number of non-squamous inflammatory cells in
induced sputum.
Induced sputum Absolute numbers (104/ml) Percentage (%)
Total cell count* 139.7 (77.9–311.3) -
Neutrophils 101.6 (46.8–228.5) 72.8 (59.9–81.7)
Macrophages 31.1 (17.9–61.1) 22.1 (14.8–33.2)
Eosinophils 1.3 (0.4–4.5) 1.1 (0.3–2.2)
Lymphocytes 2.2 (1.1–6.8) 1.7 (1.2–2.3)
Epithelial cells 1.4 (0.6–3.4) 1.0 (0.3–2.3)
Data are presented as median (25th–75th percentile).
*Total cell count refers to the number of non-squamous cells in induced
sputum.
doi:10.1371/journal.pone.0043124.t002
Table 3. TLR2 SNPs and FEV1 level at baseline and FEV1 decline.
SNP FEV1 level (ml) p FEV1 decline (ml/yr) p
B (95%CI) E (95%CI)
rs1898830 a 295.5 (2222.8–31.8) 0.140 22.4 (24.4–20.4) 0.021
b 2267.9 (2522.8–213.2) 0.039 5.2 (1.4–9.0) 0.008
rs3804099 a 140.8 (28.3–289.9) 0.064 1.5 (20.9–3.8) 0.219
b 118.6 (266.9–304.1) 0.208 3.1 (0.2–5.9) 0.036
rs3804100 a 116.3 (257.9–290.5) 0.188 2.5 (20.2–5.2) 0.073
rs1816702 a 45.8 (2102.7–194.2) 0.542 0.1 (22.3–2.4) 0.977
b 169.9 (2164.5–504.4) 0.316 28.2 (212.9–23.4) 0.001
rs11938228 a 273.0 (2202.4–56.5) 0.266 22.2 (24.2–20.1) 0.042
b 2240.2 (2450.3–230.1) 0.025 3.1 (20.2–6.3) 0.065
rs7656411 a 185.6 (55.1–316.2) 0.006 1.9 (20.2–4.0) 0.080
b 237.6 (2300.8–225.6) 0.778 8.6 (4.7–12.4) 1.361025
rs5743704 a 114.4 (2123.0–351.8) 0.341 22.8 (26.5–0.9) 0.130
rs5743708 a 272.1 (2268.8–124.7) 0.469 20.1 (23.1–2.8) 0.931
rs4696480 a 170.2 (22.6–317.8) 0.024 21.7 (24.1–0.6) 0.143
b 108.2 (262.1–278.5) 0.210 1.1 (21.6–3.8) 0.413
FEV1 level adjusted for age, gender, height, pack-year, current smoking; FEV1 decline adjusted for FEV1 baseline, age, gender, height, current smoking, treatment, the
period when there is a change in treatment and its interaction with treatment and their interaction with time; a = heterozygotes vs. wild-type; b = homozygote variant
vs. wild-type, p = p-value.
doi:10.1371/journal.pone.0043124.t003
TLR2 and TLR4 SNPs and COPD
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Individuals homozygote for rs10759931 had significantly higher
sputum neutrophil and macrophage numbers at baseline com-
pared with wild-type individuals [0.88 (0.18–1.58) and 0.75 (0.13–
1.38) respectively] as well as a higher increase in numbers over
time [0.05 (0.02–0.08) and 0.07 (0.04–0.10) respectively] (Figure 3).
Individuals heterozygote for the same SNP (rs10759931) had a
significantly higher number of eosinophils at baseline and
individuals homozygote for the same SNP a significantly higher
increase number of eosinophils over time compared with wild-type
individuals [0.93 (0.20–1.65) and 0.06 (0.02–0.11) respectively]
(Figure 3).
Individuals carrying rs913930 had significantly lower numbers
of macrophages and eosinophils at baseline compared with wild-
type individuals [20.5 (20.9–20.1) and 21.7 (22.8–20.6) in
heterozygote and homozygote variants respectively] and a
decrease in numbers over time [20.03 (20.05–20.01) and
20.07 (20.13–20.01) respectively] (Table S8 and Table S9).
Individuals heterozygote for rs2770150 had a significantly lower
number of neutrophils at baseline compared with wild-type
individuals [20.48 (20.94–20.03)] and a larger fall in numbers
of neutrophils, macrophages, eosinophils and epithelial cells over
time [20.03 (20.05; 20.01), 20.02 (20.04–20.001), 20.05
(20.08–20.02) and 20.04 (20.07–20.002) respectively] (Table
S7, Table S8, Table S9 and Table S10).
Discussion
This is the first study investigating comprehensively the genetic
contribution of Toll-like receptors to both the severity and the
progression of COPD with respect to lung function and
inflammation. We investigated 26 tagging SNPs in TLR2 and
TLR4 and showed consistent associations with the level and
decline of FEV1 as well as with inflammatory cell numbers in
induced sputum at baseline and their changes over time.
We found that many SNPs in TLR2 and TLR4 were of
relevance: 4 out of 9 SNPs in TLR2 were significantly associated
with the level of lung function, 2 with a lower level of FEV1
(rs1898830 and rs11938228) and 2 with a higher level of FEV1
(rs7656411 and rs4696480). The SNPs rs1898830, rs3804099 and
rs7656411 were significantly associated with less FEV1 decline and
the intronic SNPs rs1898830, rs1816702 and rs11938228 with
accelerated FEV1 decline. The SNP rs11938228 was also
associated with an increase in numbers of neutrophils, macro-
phages and eosinophils in sputum at baseline and with a decrease
in numbers of neutrophils over time from baseline, suggesting that
Figure 1. rs11938228 and inflammatory cells in induced sputum. Circles represent the regression coefficient (estimate) and vertical bars the
95% confidence interval (CI); Nr. = number of subjects; Wild type was set as the reference category (CC); At baseline analyses are adjusted for age,
gender, height, packyears and smoking status; Over time analyses are adjusted for age, gender, height, smoking status, the corresponding initial
baseline variable, treatment, the period when there is a change in treatment and its interaction with treatment and the interaction of all variables
with time.
doi:10.1371/journal.pone.0043124.g001
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these features may either be associated or be influenced by one
underlying mechanism. Rs3804099 was significantly associated
with a decrease in neutrophils and macrophages over time.
None of the SNPs in TLR4 was associated with the level of
FEV1, whereas 11 out of 17 SNPs in TLR4 were significantly
associated with accelerated (n= 7) or reduced decline of FEV1
(n = 4). Rs12377632 and rs10759931 in TLR4 were consistently
associated with higher numbers of inflammatory cells in induced
sputum at baseline and an increase in numbers of inflammatory
cells in induced sputum over time from baseline. The other SNPs
were associated with either the level or the changes in sputum
inflammatory cell numbers from baseline.
Toll-like receptors form a component of the innate immune
response which is the first line of defence against invading
microorganisms. In humans, 10 functional TLRs have been
described [19]. Each TLR expressed in the cellular membrane
recognizes molecules such as the lipoproteins of gram-positive
bacteria (TLR2) and LPS of gram-negative bacteria (TLR4) [19].
TLRs have been broadly studied in the perspective of microbial
and viral infections, inflammation and immune cells [20], but not
extensively in COPD. Findings on TLR2 expression on alveolar
macrophages, sputum neutrophils and blood monocytes [5,21,22]
do suggest a role for this receptor in inflammation that is a
characteristic of COPD.
Even less is known on SNPs in TLR2 and TLR4 and COPD.
Two SNPs in TLR2 (rs1898830 and rs4696480) are associated
with a lower respectively higher level of FEV1 in the current study
and rs1898830 additionally with the decline of FEV1, suggesting
that this SNP might be involved in the progression of the disease as
well. This is compatible with observations in asthma where the
same SNPs have been shown to modify the effect of PM2.5
exposure on the prevalence of asthma from birth up to 8 years of
Table 4. TLR4 SNPs and FEV1 level at baseline and FEV1 decline.
SNP FEV1 level (ml) p FEV1 decline (ml/yr) p
B (95%CI) E (95%CI)
rs2770150 a 33.3 (297.8–164.3) 0.615 1.7 (20.3–3.7) 0.097
b 193.2 (286.3–472.6) 0.173 21.6 (27.1–4.1) 0.587
rs2737190 a 11.3 (2123.1–145.5) 0.869 0.8 (21.3–2.7) 0.469
b 84.6 (2167.3–336.5) 0.507 25.0 (28.7–21.3) 0.008
rs10759932 a 236.9 (2195.6–121.8) 0.646 22.0 (24.3–0.3) 0.084
b 219.8 (2503.8–463.6) 0.935 24.6 (210.4–1.3) 0.123
rs1927911 a 56.5 (277.5–190.4) 0.405 20.2 (22.2–1.9) 0.872
b 136.6 (2144.8–417.9) 0.338 25.4 (29.6–21.1) 0.014
rs4986790 a 271.9 (2277.5–133.8) 0.490 0.8 (22.4–3.9) 0.633
rs11536889 a 27.7 (2147.2–131.9) 0.914 0.8 (21.4–2.9) 0.470
b 2230.8 (2613.6–151.9) 0.234 21.2 (26.6–4.3) 0.682
rs7856729 a 144.8 (28.3–297.9) 0.063 1.5 (21.0–3.9) 0.244
b 26.3 (2467.0–454.5) 0.979 27.3 (213.8–20.8) 0.028
rs7846989 a 2168.6 (2348.2–11.0) 0.065 20.9 (23.5–1.7) 0.489
b 260.9 (2732.5–610.7) 0.858 211.0 (220.2–21.8) 0.020
rs7037117 a 46.8 (2245.6–339.1) 0.743 25.4 (29.2–21.7) 0.005
b 246.7 (2301.1–794.4) 0.360 29.1 (215.1–23.2) 0.003
rs10983755 a 2118.2 (2412.6–176.3) 0.428 23.3 (27.8–1.2) 0.151
b 243.9 (2712.5–624.7) 0.897 210.7 (219.9–21.5) 0.023
rs12377632 a 27.5 (2150.1–135.1) 0.917 2.4 (0.1–4.7) 0.040
b 2110.4 (2309.1–88.3) 0.273 0.4 (22.7–3.5) 0.793
rs11536857 a 292.9 (2332.3–146.4) 0.443 20.6 (24.4–3.2) 0.753
b 2180.2 (2484.4–123.9) 0.243 0.2 (24.1–4.5) 0.923
rs11536869 a 2106.1 (2491.7–279.5) 0.586 6.4 (1.1–11.7) 0.019
rs913930 a 215.6 (2157.6–126.3) 0.828 1.4 (20.7–3.5) 0.204
b 62.9 (2184.3–310.1) 0.615 1.8 (22.4–5.9) 0.399
rs11536897 a 110.2 (2115.5–335.9) 0.335 7.5 (3.8–11.3) 9.161025
rs10759931 a 23.3 (2152.9–146.4) 0.966 2.6 (0.2–4.9) 0.033
b 294.1 (2292.2–104.0) 0.348 20.9 (23.9–2.1) 0.534
rs11536878 a 143.9 (228.4–316.1) 0.101 3.5 (0.5–6.4) 0.021
b 317.1 (252.2–686.4) 0.092 25.7 (214.8–3.4) 0.217
FEV1 level adjusted for age, gender, height, pack-year, current smoking; FEV1 decline adjusted for FEV1 baseline, age, gender, height, current smoking, treatment, the
period when there is a change in treatment and its interaction with treatment and their interaction with time; a = heterozygotes vs. wild-type; b = homozygote variant
vs. wild-type, p = p-value.
doi:10.1371/journal.pone.0043124.t004
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age [23]. Rs1898830, located in intron 1, was previously
associated with TLR2-mediated cellular activation [24]. The
authors suggested that this effect might be caused by the effect of
the rs13150331 on transcriptional activities of the TLR2 gene
promoter, a SNP in the 59-flanking region that is in strong LD with
rs1898830 [24]. The observed associations in the current study
may also be due to the effects of other SNPs in TLR2 in LD with
the intronic SNPs rs1898830 and rs4696480. However, there is
accumulating evidence that mutations in the splice, donor and
acceptor sites or enhancer, intron and promoter elements may all
be important in genetic expression and regulation [25]. Therefore,
functional assays are of interest to elucidate the molecular
mechanisms underlying these associations.
We confirmed previous observations that there is no significant
association of rs5743708 (Arg753Gln), a SNP shown to affect
transmembrane signalling of TLR2 [26], with progression of
COPD [7]. Furthermore there was no association with numbers of
inflammatory cells in induced sputum, suggesting that this specific
SNP may have no impact on COPD.
Interestingly, rs11938228, an intronic TLR2 SNP that has not
been previously studied, was associated with a lower level of FEV1
and increased numbers of inflammatory cells in induced sputum at
baseline, suggesting that this SNP negatively affects the severity of
COPD.
A reduced TLR4 gene expression has been found in nasal
epithelium of smokers and severe COPD patients [27]. Other
studies showed that expression of TLR4 mRNA is inhibited by
LPS in a mouse macrophage cell line [28] and stimulated in
human neutrophils and monocytes [29]. This apparent discrep-
ancy may reflect the differences in cell type and/or differentiation
stages [20]. These findings are of interest given our observation
that different SNPs in TLR4 are associated either with the number
of neutrophils or the number of macrophages (Table S8 and Table
S9). Two SNPs in TLR4 namely rs12377632 and rs10759931 were
consistently associated with lung function and inflammation.
However, the results from baseline and longitudinal analyses for
heterozygotes and homozygotes separately require careful inter-
pretation. For instance both heterozygotes and homozygotes for
rs12377632 had a non-significantly lower level of lung function,
but a significantly higher number of inflammatory cells in induced
sputum, suggesting that this particular SNP may be involved in
inflammatory processes representing the first line of defence as
reflected in sputum. Additionally, heterozygote individuals for
rs12377632 had less lung function decline, while homozygote
individuals for the same SNP had a significantly higher number of
Figure 2. rs12377632 and inflammatory cells in induced sputum. Circles represent the regression coefficient (estimate) and vertical bars the
95% confidence interval (CI); Nr. = number of subjects; Wild type was set as the reference category (TT); At baseline analyses are adjusted for age,
gender, height, packyears and smoking status; Over time analyses are adjusted for age, gender, height, smoking status, the corresponding initial
baseline variable, treatment, the period when there is a change in treatment and its interaction with treatment and the interaction of all variables
with time.
doi:10.1371/journal.pone.0043124.g002
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inflammatory cells over time. This may signify that disease
modification can be achieved for particular genotypes in COPD
and that changes in induced sputum may represent an activation
of the first line of defence yet this is not interrelated with changes
in lung function.
Rs10759931 in TLR4 may have functional consequences on
TLR4 expression or signalling activity given its location in the
promoter region. This may influence exclusively innate immunity
and inflammation, which in turn may affect COPD severity and
progression. Therefore, its association with less accelerated FEV1
decline and increase in numbers of macrophages over time is
intriguing since one generally would anticipate that an increase in
inflammatory burden associates with accelerated lung function
decline. It is thus difficult to reconcile these two observations. This
may be due to other genetic effects interacting with this particular
SNP and/or differential effects of this SNP on many other
underlying mechanisms of changes in lung function, like extracel-
lular matrix turnover or effects on oxidative stress responses.
Moreover, gene expression profiling combined with genetics
should elucidate whether this SNP indeed is an eQTL (expression
quantitative trait locus). Since rs10759931 could be a GATA2
binding site [23], future studies should unravel how the studied
SNPs functionally contribute to COPD severity and progression.
Only 2 SNPs in TLR4 have been previously investigated with
respect to COPD; Asp299Gly (rs498670) and Thr399Ile
(rs498671) [8–10]. Rs498670 appeared not to be present among
patients with COPD who had never smoked [8] and there were no
homozygote variants for rs498670 in smokers from the general
population (.10 packyears and .40 years of age) [8], comparable
to our study. We also confirm the previous findings that the
presence of the TLR4 rs498670 did not have any significant
impact on lung function level [8] and extend this observation by
showing that it was also not significantly associated with FEV1
decline. This indicates that rs498670 has no impact on the severity
of COPD at a population level as well as in patients with
established COPD.
We here show that rs2770150 was consistently associated with
lower numbers of inflammatory cells in induced sputum in COPD
although the effect size was small. This promoter SNP might thus
positively influence inflammation in COPD patients. Since
signalling through TLR2 and TLR4 by hyaluronan may be
important in the maintenance of epithelial integrity in the lung
after inflammatory insults and in repair [30], it could be that TLR2
and TLR4 SNPs are also exhibiting effects in the inflammatory
processes in COPD in order to down regulate detrimental signals.
More studies are clearly needed to validate these findings and to
Figure 3. rs10759931 and inflammatory cells in induced sputum. Circles represent the regression coefficient (estimate) and vertical bars the
95% confidence interval (CI); Nr. = number of subjects; Wild type was set as the reference category (GG); At baseline analyses are adjusted for age,
gender, height, packyears and smoking status; Over time analyses are adjusted for age, gender, height, smoking status, the corresponding initial
baseline variable, treatment, the period when there is a change in treatment and its interaction with treatment and the interaction of all variables
with time.
doi:10.1371/journal.pone.0043124.g003
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understand the mechanism by which the TLR2 and TLR4
polymorphisms affect the pathological role of TLRs in the
signalling pathways involved in COPD, in particular taking into
account the effects on level of expression of these receptors on
different cell types. For instance there is an increased expression of
TLR4 and TLR9 on lung CD8+ T cells [31].
It has been speculated that TLRs could delay FEV1 decline and
thus serve as a therapy target for COPD patients [31,32]. Of
reference to our study, COPD patients have reduced TLR4
expression in epithelial cells and corticosteroids dose dependently
reduced TLR4 mRNA in an epithelial cell line [27] and increased
TLR2 expression [33]. Our patients used inhaled corticosteroids
in the randomized GLUCOLD study [16]. Therefore, we adjusted
for the period with a change in treatment and its interaction with
treatment to avoid any interference with the treatment response.
Due to the relatively low number of participants in the study and
hence low power, a formal study on gene-treatment interaction
was not feasible. However, even with the low numbers of
individuals, we were able to find consistent associations of SNPs
in TLR2 and TLR4 with level and decline of lung function and
number of inflammatory cells in induced sputum. Although effects
on lung function decline are small, they are consistent for different
SNPs. Given the consistency of our results, it is of importance that
future studies with a larger sample size of COPD patients confirm
the clinical significance of our findings.
In the current dataset we did not apply a multiple testing
correction (i.e. Bonferroni) given the clustering of outcome
variables, which might occur jointly at high or low levels account
(e.g. a Pearson’s correlation coefficient r = 0.79 for macrophages
and lymphocytes in induced sputum) or their definition as each
other’s ratios [16].
In summary, previous studies focused on functional SNPs only
and studied COPD development exclusively, whereas our study is
the first with longitudinal data showing that tagging SNPs in the
TLR2 and TLR4 genes are associated with the level and decline of
lung function as well as with (changes in) numbers of inflammatory
cells in induced sputum. These different associations provide
insights for future investigations on how these polymorphisms may
produce different signatures of genes’ activation and how they
could eventually contribute to pharmacogenetics in COPD
management, which will result in more accurate and targeted
therapy.
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